Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC31H32N2O4 |
InChIKeyGHGYXSITKLEDOE-SANMLTNESA-N |
CAS Registry3025012-65-8 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | China | 01 Aug 2024 |





